CVS Health Corp (NYSE: CVS) closed the day trading at $73.84 down -0.71% from the previous closing price of $74.37. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 8492220 shares were traded.
Ratios:
For a better understanding of CVS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.94. For the most recent quarter (mrq), Quick Ratio is recorded 0.63 and its Current Ratio is at 0.86. In the meantime, Its Debt-to-Equity ratio is 1.04 whereas as Long-Term Debt/Eq ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $88.
On December 22, 2023, HSBC Securities started tracking the stock assigning a Buy rating and target price of $94.
Evercore ISI Upgraded its In-line to Outperform on September 19, 2023, whereas the target price for the stock was revised from $81 to $83.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 when Shah Prem S sold 29,473 shares for $76.95 per share. The transaction valued at 2,267,947 led to the insider holds 39,765 shares of the business.
LUDWIG EDWARD J bought 2,000 shares of CVS for $140,930 on Nov 03. The Director now owns 20,630 shares after completing the transaction at $70.47 per share. On Aug 03, another insider, Clark James David, who serves as the SVP, Cont & Chief Acct Officer of the company, sold 25,759 shares for $74.92 each. As a result, the insider received 1,930,004 and left with 4,698 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVS now has a Market Capitalization of 92.92B and an Enterprise Value of 160.85B. As of this moment, CVS’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.42, and their Forward P/E ratio for the next fiscal year is 8.00. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.26 while its Price-to-Book (P/B) ratio in mrq is 1.24. Its current Enterprise Value per Revenue stands at 0.45 whereas that against EBITDA is 8.84.
Stock Price History:
Over the past 52 weeks, CVS has reached a high of $83.26, while it has fallen to a 52-week low of $64.41. The 50-Day Moving Average of the stock is 76.52, while the 200-Day Moving Average is calculated to be 71.82.
Shares Statistics:
Over the past 3-months, CVS traded about 11.26M shares per day on average, while over the past 10 days, CVS traded about 8.43M shares per day. A total of 1.29B shares are outstanding, with a floating share count of 1.26B. Insiders hold about 0.18% of the company’s shares, while institutions hold 82.46% stake in the company. Shares short for CVS as of Feb 15, 2024 were 30.76M with a Short Ratio of 2.73, compared to 42.52M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.44% and a Short% of Float of 2.45%.
Dividends & Splits
CVS’s forward annual dividend rate is 2.48, up from 2.42 a year ago. Against a Trailing Annual Dividend Yield of 3.25%, it implies a Forward Annual Dividend Yield of 3.60%. The stock’s 5-year Average Dividend Yield is 2.87. The current Payout Ratio is 38.34% for CVS, which recently paid a dividend on Feb 01, 2024 with an ex-dividend date of Jan 19, 2024. Stock splits for the company last occurred on Jun 07, 2005 when the company split stock in a 2:1 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 19 analysts. On average, analysts expect EPS of $1.73 for the current quarter, with a high estimate of $2.02 and a low estimate of $1.63, while EPS last year was $2.2. The consensus estimate for the next quarter is $2.19, with high estimates of $2.34 and low estimates of $1.88.
Analysts are recommending an EPS of between $8.41 and $8.11 for the fiscal current year, implying an average EPS of $8.32. EPS for the following year is $9.22, with 21 analysts recommending between $9.53 and $9.05.
Revenue Estimates
16 analysts predict $89.25B in revenue for the current quarter. It ranges from a high estimate of $91.18B to a low estimate of $87.42B. As of the current estimate, CVS Health Corp’s year-ago sales were $80.81B, an estimated increase of 10.40% from the year-ago figure. For the next quarter, 16 analysts are estimating revenue of $92.22B, an increase of 3.70% less than the figure of $10.40% in the same quarter last year. There is a high estimate of $93.49B for the next quarter, whereas the lowest estimate is $90.93B.
A total of 20 analysts have provided revenue estimates for CVS’s current fiscal year. The highest revenue estimate was $377.36B, while the lowest revenue estimate was $363B, resulting in an average revenue estimate of $370.59B. In the same quarter a year ago, actual revenue was $357.78B, up 3.60% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $392.69B in the next fiscal year. The high estimate is $402.61B and the low estimate is $384.03B. The average revenue growth estimate for next year is up 6.00% from the average revenue estimate for this year.
